Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice

par Ravaud, A, Bedane, C, Geoffrois, L, Lesimple, T, Delaunay, M
Publié 1999

EPOCK study protocol: a mixed-methods research program evaluating cancer care coordination nursing occupations in France as a complex intervention

par Colombani, F., Sibé, M., Kret, M., Quintard, B., Ravaud, A., Saillour-Glénisson, F.
Publié dans BMC Health Serv Res (2019)

Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension.

par Calès, P, Grasset, D, Ravaud, A, Meskens, C, Blanc, M, Vinel, J P, Cotonat, J, Pascal, J P
Publié 1989

Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding.

par Calès, P, Desmorat, H, Vinel, J P, Caucanas, J P, Ravaud, A, Gerin, P, Brouet, P, Pascal, J P
Publié 1990

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

par Ravaud, A., Négrier, S., Cany, L., Merrouche, Y., Le Guillou, M., Blay, J. Y., Clavel, M., Gaston, R., Oskam, R., Philip, T.
Publié 1994

A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.

par Ravaud, A., Legrand, E., Delaunay, M. M., Bussières, E., Coulon, V., Cany, L., Huet, S., Verdier, D., Kind, M., Chomy, F.
Publié 1995

Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial

par Ravaud, A, Delaunay, M, Chevreau, C, Coulon, V, Debled, M, Bret-Dibat, C, Courbon, F, Gualde, N, Bui, B Nguyen
Publié 2001

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II t...

par Ravaud, A, Trufflandier, N, Ferrière, J M, Debled, M, Palussière, J, Cany, L, Gaston, R, Mathoulin-Pélissier, S, Bui, B N
Publié 2003

Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials.

par Ravaud, A., Bui, N. B., Coindre, J. M., Lagarde, P., Tramond, P., Bonichon, F., Stöckle, E., Kantor, G., Trojani, M., Chauvergne, J.
Publié 1992

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

par Rugo, H. S., Hortobagyi, G. N., Yao, J., Pavel, M., Ravaud, A., Franz, D., Ringeisen, F., Gallo, J., Rouyrre, N., Anak, O., Motzer, R.
Publié dans Ann Oncol (2016)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

par Bracarda, S, Hutson, T E, Porta, C, Figlin, R A, Calvo, E, Grünwald, V, Ravaud, A, Motzer, R, Kim, D, Anak, O, Panneerselvam, A, Escudier, B
Publié 2012

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

par Staehler, M, Motzer, R J, George, D J, Pandha, H S, Donskov, F, Escudier, B, Pantuck, A J, Patel, A, DeAnnuntis, L, Bhattacharyya, H, Ramaswamy, K, Zanotti, G, Lin, X, Lechuga, M, Serfass, L, Paty, J, Ravaud, A
Publié dans Ann Oncol (2018)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

par Motzer, R.J., Tannir, N.M., McDermott, D.F., Frontera, O. Arén, Melichar, B., Choueiri, T.K., Plimack, E.R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C.K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C.H., Tomita, Y., Castellano, D., Rini, B.I., Chen, A.C., Mekan, S., McHenry, M.B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H.J., Escudier, B.
Publié dans N Engl J Med (2018)